Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management
Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cu...
Saved in:
Main Authors: | K. Chanprapaph, V. Vachiramon, P. Rattanakaemakorn |
---|---|
Other Authors: | Mahidol University |
Format: | Review |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/34433 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases
by: Kumutnart Chanprapaph, et al.
Published: (2018) -
Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients
by: Leena Chularojanamontri, et al.
Published: (2020) -
Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, Srinivasaraghavan, et al.
Published: (2017) -
Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, S, et al.
Published: (2020) -
Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors
by: Eng, H.T., et al.
Published: (2014)